NRXS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

1 Analyst Rating

Wall Street analysts forecast NRXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXS is USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.50

Averages

High

2.50

Current: 0.000

Low

2.50

Averages

High

2.50

Craig-Hallum

Buy

maintain

$7 -> $8

2025-12-22

Reason

Craig-Hallum

Price Target

$7 -> $8

2025-12-22

maintain

Buy

Reason

Craig-Hallum raised the firm's price target on Neuraxis to $8 from $7 and keeps a Buy rating on the shares after the company announced that they have been included in coverage from a large, national payer. This coverage expansion adds approximately 45M lives, bringing total national coverage for IBStim to nearly 100M. The Anthem win adds coverage for as much as 20% of NeurAxis's pediatric opportunity, and the firm believes it really unlocks the opportunity itself.

Craig-Hallum

Chase Knickerbocker

Buy

initiated

2025-06-17

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

2025-06-17

initiated

Buy

Reason

Craig-Hallum analyst Chase Knickerbocker initiated coverage of Neuraxis with a Buy rating and $7 price target.

Craig-Hallum

Chase Knickerbocker

Buy

initiated

2025-06-17

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

2025-06-17

initiated

Buy

Reason

As previously reported, Craig-Hallum analyst Chase Knickerbocker initiated coverage of Neuraxis with a Buy rating and $7 price target. The firm says this is a classic overlooked micro-cap medtech story that it believes will appear to be an overnight success story, though it was many years in the making. Neuraxis is introducing innovation into a space that does not get a lot of attention, namely pediatric functional abdominal pain. Craig-Hallum is highlighting the company's product IB-Stim as a potentially transformative therapy for pediatric functional abdominal pain disorders. The company targets a $3.7B market in severely debilitated patients, and the firm believes Neuraxis could very realistically reach $130M in revenue at just 4% penetration.

Valuation Metrics

The current forward P/E ratio for Neuraxis Inc (NRXS.A) is -6.66, compared to its 5-year average forward P/E of -17.01. For a more detailed relative valuation and DCF analysis to assess Neuraxis Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-17.01

Current PE

-6.66

Overvalued PE

-4.69

Undervalued PE

-29.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.71

Current EV/EBITDA

-5.59

Overvalued EV/EBITDA

0.63

Undervalued EV/EBITDA

-2.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.54

Current PS

8.48

Overvalued PS

4.16

Undervalued PS

0.92

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NRXS News & Events

Events Timeline

No data

News

6.5

01-06NASDAQ.COM

Meta Platforms Sees 3.6% Stock Growth Driven by User Engagement

7.5

2025-12-19Newsfilter

NeurAxis Secures Major Medical Policy Coverage for PENFS, Impacting 45 Million Members

7.0

2025-11-11SeekingAlpha

NeurAxis Prepares for 2026 Commercial Launch Amid Ongoing Double-Digit Growth and Approaching CPT Code Milestone

People Also Watch

Frequently Asked Questions

What is Neuraxis Inc (NRXS) stock price today?

The current price of NRXS is 4.66 USD — it has increased 0.65 % in the last trading day.

What is Neuraxis Inc (NRXS)'s business?

Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.

What is the price predicton of NRXS Stock?

Wall Street analysts forecast NRXS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXS is USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Neuraxis Inc (NRXS)'s revenue for the last quarter?

Neuraxis Inc revenue for the last quarter amounts to 811.41K USD, increased 21.72 % YoY.

What is Neuraxis Inc (NRXS)'s earnings per share (EPS) for the last quarter?

Neuraxis Inc. EPS for the last quarter amounts to -0.24 USD, decreased -4.00 % YoY.

What changes have occurred in the market's expectations for Neuraxis Inc (NRXS)'s fundamentals?

The market is revising Downward the revenue expectations for NeurAxis, Inc. (NRXS) for FY2025, with the revenue forecasts being adjusted by -14.35% over the past three months. During the same period, the stock price has changed by 53.29%.

How many employees does Neuraxis Inc (NRXS). have?

Neuraxis Inc (NRXS) has 21 emplpoyees as of January 09 2026.

What is Neuraxis Inc (NRXS) market cap?

Today NRXS has the market capitalization of 49.43M USD.